10 days to go until the first deliveries of the Pfizer vaccine are expected in hospitals, and NHS staff will be getting jabbed from then -
“Fortunately, we found that none of these mutations are making COVID-19 spread more rapidly, but we need to remain vigilant and continue monitoring new mutations, particularly as vaccines get rolled out.”
This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission.
New research reveals promising antiviral drug that can be taken orally.
New drug rapidly blocks SARS-CoV-2 transmission in animal model
In a new study published in the scientific journal Cell, the team from Gladstone, UC Berkeley, and UCSF has outlined the technology for a CRISPR-based test for COVID-19 that uses a smartphone camera to provide accurate results in under 30 minutes. [...]
Not only can their new diagnostic test generate a positive or negative result, it also measures the viral load (or the concentration of SARS-CoV-2, the virus that causes COVID-19) in a given sample.
cost-effective and portable and can be integrated with smartphones for easy and rapid diagnosis of SARS-CoV-2.
quantify the viral RNA load
Dr John Campbell did a review of these findings in a recent video. He seems to be somewhat sceptical of their conclusions which I find a little puzzling, given his usual mantra of following the evidence and his normal tendency to put faith in research from reputable scientists and institutions using evidence-based medicine.Invermectin, a cheap,safe anti-parasitic drug that has been available for decades has been producing good results in multiple trials for a while now. I’m surprised it isn’t more widely discussed as a treatment option. Perhaps it will be a ‘dexamethasone’ type breakthrough soon ?
He added that “what is truly remarkable — this was a gift to us — ivermectin has high activity against COVID-19.”
“All studies showed positive benefits — the majority showed a decrease in mortality, decreases in hospitalization,” Kory said.
In light of the positive data on ivermectin in COVID-19, the researchers called on national and global health authorities — including the NIH, WHO and the CDC — to examine the data.”
Numerous studies have provided evidence supporting the use of ivermectin to prevent and treat COVID-19, according to the Frontline COVID-19 Critical Care Alliance.www.healio.com
Dr John Campbell did a review of these findings in a recent video. He seems to be somewhat sceptical of their conclusions which I find a little puzzling, given his usual mantra of following the evidence and his normal tendency to put faith in research from reputable scientists and institutions using evidence-based medicine.
I've read their full paper and it seems to be based on a lot of well-conducted scientific studies. Admittedly, as Dr Campbell points out, only half of them have been peer-reviewed so far but by the same token that means that fully 50% of them have been - and there are a large number of them, all pointing to the same conclusion.
Pascal Soriot, chief executive of AstraZeneca, told the Sunday Times: "We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else.
NERVTAG investigated 915 cases of the new variant in the south east through November/early December. 4 of those cases were probable reinfections. Assuming 10% of people had had the disease previously, that would suggest 5% possible reinfection rate. That is still a high protection rate comparable with a vaccine.The Geordies have been looking into reinfection rates among their healthcare workers, and have found good immunity levels *so far*, which bodes very well.
They had data for 11103 staff since the first wave, 1038 of whom were confirmed to have SARS-COV 2 by PCR test and antibody test during the first wave, which is a fairly decent sample size, (especially given that these good people are working at the high end of the risk of infection spectrum.)
Of those 1038, nil have been reinfected in the second wave but there were 290 infections in their colleagues (who were not infected during the first wave)
So 6-7 month immunity as a minimum looks good.
Obviously this was only a study of working age people, but nevertheless it bodes well.
Well done to the Newcastle Upon Tyne Hospitals NHS trust for being proactive in looking at this as the months progressed!
Journal Pre-proof for anybody interested -